Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
EBITDA is expected to be between $30 million and $33 million, reflecting an adjusted EBITDA margin of 10% to 12%
Abstract Incretin-based therapies with glucagon-like peptide-1 receptor agonists (GLP-1RA) are already established in the treatment of type 2 diabetes (T2D)
The evidence base is overwhelmingly preclinical, and there are no completed, published Phase 2 or 3 human efficacy trials only early-stage safety work [9]
Always verify your specific vial concentration before drawing
:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)
US$ 23.91
US$ 25.23
US$ 29.04
US$ 29.27
